Physician profile
Daniel Nader
NPI 1972564169
$3,482.72
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,625 · 2020: $883 · 2021: $450 · 2022: $525.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gyrus Acmi, INC. | $1,800.00 | 2020-2022 | |
| Spiration, INC. | $750.00 | 2019 | |
| Auris Health, INC. | $280.97 | 2019 | |
| Ethicon INC. | $202.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $181.96 | 2019-2020 | |
| Genentech USA, INC. | $131.30 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.65 | 2019-2020 | |
| Lilly USA, LLC | $19.24 | 2020 | |
| Janssen Biotech, INC. | $18.20 | 2019 | |
| Array Biopharma INC | $16.08 | 2019 | |
| Seagen INC. | $14.25 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.